Delayed referrals, diagnoses undermine cancer patients' faith in health care system
the ONA take:
Analysis of data from a survey conducted by Cancer Research UK scientists revealed that timeliness of referral for cancer tests can have a significant impact on patients’ overall satisfaction with their care and their health care team.
Of the nearly 60,000 survey respondents whose diagnoses were made through their GPs, 23% had been seen three or more times before a referral for cancer tests was given.
Furthermore, these patients were more likely to report negative experiences across 10 of 12 different aspects of their care compared with those patients who were referred after one or two visits with their GPs.
Aspects of care in which patients were dissatisfied included the way they were informed of their diagnosis, how well hospital and GPs worked together to provide care, and confidence and trust in ward nurses.
Although diagnostic delays can be caused by the difficulty in distinguishing cancer symptoms from other diseases and a lack of accurate and easy-to-use tests, the survey results demonstrate the significance of early diagnosis on patients’ overall experience with cancer care.
The researchers report that timeliness of diagnosis is an important factor in patients’ overall experience in their cancer journey.
Timeliness of referral for cancer tests can have a significant impact on patients’ overall satisfaction.
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Immune Thrombocytopenia (Fact Sheet)
- Novel 3D Marker Reduces Radiation, Improves Cosmesis in Breast Conserving Surgery
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|